pd 173074 has been researched along with Bladder Cancer in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, JH | 1 |
| Kwak, Y | 1 |
| Song, C | 1 |
| Roh, EJ | 1 |
| Oh, CH | 1 |
| Lee, SH | 1 |
| Sim, T | 1 |
| Choi, JH | 1 |
| Yoo, KH | 1 |
| Turner, LD | 1 |
| Trinh, CH | 1 |
| Hubball, RA | 1 |
| Orritt, KM | 1 |
| Lin, CC | 1 |
| Burns, JE | 1 |
| Knowles, MA | 2 |
| Fishwick, CWG | 1 |
| Miyake, M | 1 |
| Ishii, M | 1 |
| Koyama, N | 1 |
| Kawashima, K | 1 |
| Kodama, T | 1 |
| Anai, S | 1 |
| Fujimoto, K | 1 |
| Hirao, Y | 1 |
| Sugano, K | 1 |
| Lamont, FR | 1 |
| Tomlinson, DC | 1 |
| Cooper, PA | 1 |
| Shnyder, SD | 1 |
| Chester, JD | 1 |
| Chell, V | 1 |
| Balmanno, K | 1 |
| Little, AS | 1 |
| Wilson, M | 1 |
| Andrews, S | 1 |
| Blockley, L | 1 |
| Hampson, M | 1 |
| Gavine, PR | 1 |
| Cook, SJ | 1 |
5 other studies available for pd 173074 and Bladder Cancer
| Article | Year |
|---|---|
Synthesis of novel arylaminoquinazolinylurea derivatives and their antiproliferative activities against bladder cancer cell line.
Topics: Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Quinazolines; Urea; | 2016 |
From Fragment to Lead: De Novo Design and Development toward a Selective FGFR2 Inhibitor.
Topics: Cell Proliferation; Drug Design; Drug Development; Humans; Phosphorylation; Protein Kinase Inhibitor | 2022 |
1-tert-butyl-3-[6-(3,5-dimethoxy-phenyl)-2-(4-diethylamino-butylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea (PD173074), a selective tyrosine kinase inhibitor of fibroblast growth factor receptor-3 (FGFR3), inhibits cell proliferation of bladder cancer carryi
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p27; Female; G1 Pha | 2010 |
Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.
Topics: Animals; Apoptosis; Benzimidazoles; Blotting, Western; Carcinoma, Transitional Cell; Cell Cycle; Cel | 2011 |
Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.
Topics: Antineoplastic Agents; Benzamides; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Fe | 2013 |